InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,320.00
(
0.12%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
73.47
(
-0.57%
)
Bitcoin
63,399.30
(
-0.35%
)
Post# of 964
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

midastouch017

Send PM Follow Ignore
Followers 144
Posts 27707
Boards Moderated 3
Alias Born 02/07/2004

midastouch017

Re: None

Tuesday, 08/16/2022 8:00:59 AM

Tuesday, August 16, 2022 8:00:59 AM

Post# of 964
JMP Securities Sticks to Their Buy Rating for Gamida Cell (GMDA)

August 15 2022 - 03:05PM

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Gamida Cell (GMDA - Research Report), with a price target of $17.00. The company's shares opened today at $3.07.According to TipRanks, Butler is an analyst with an average return of -2.8% and a 43.10% success rate. Butler covers the Healthcare sector, focusing on stocks such as Concert Pharma, Syros Pharmaceuticals, and Aquestive Therapeutics.Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $14.80, implying a 382.08% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $8.
https://www.tipranks.com/news/blurbs/jmp-securities-sticks-to-their-buy-rating-for-gamida-cell-gmda?utm_source=advfn.com&utm_medium=referral
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up